Skip to main content
. 2022 Jun 30;12:895672. doi: 10.3389/fonc.2022.895672

Figure 4.

Figure 4

Kaplan-Meier curves of RFS (A) and MSS (B) according to adjuvant regimens in patients in the Ki67 low (<30%) and Ki67 high (>=30%) group. RFS, relapse-free survival; MSS, melanoma-specific survival; TMZ, temozolomide; HDI, high-dose interferon-a2b.